Immunotherapy for brain cancer: recent progress and future promise
about
NF-κB and STAT3 in glioblastoma: therapeutic targets coming of ageSustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia.Immunotherapy response assessment in neuro-oncology: a report of the RANO working groupImmune Checkpoint in Glioblastoma: Promising and ChallengingAxitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.Distribution and characterization of tumor-associated macrophages/microglia in rat C6 glioma.Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and VaccinationLoss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma.Recent advances and future of immunotherapy for glioblastoma.Current challenges in designing GBM trials for immunotherapy.Genomic discoveries in adult astrocytomaGenetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11).Immune Checkpoint Inhibitors in Gliomas.Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.Angiogenesis inhibitors in tackling recurrent glioblastoma.Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.Immunotherapy for glioblastoma: are we finally getting closer?Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.The emerging role of galectins in high-fatality cancers.Development of bioactive materials for glioblastoma therapy.Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma.Bilateral anterior uveitis after immunotherapy for malignant melanomaPhase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
P2860
Q26830388-77BAC196-5C1D-482B-B14E-73F6032C82E0Q27334035-64D065A8-3E5B-4082-8926-7D6DBF5C6A95Q28083009-19A2AA1F-CE0E-44C0-8A8D-A28A2272DE5AQ33650058-DE8D6443-BCFF-4E44-8190-1C21E646E599Q35798966-72E8B0A6-8DB3-4BB8-AEA9-F5753E3CD9E3Q35815273-3CBE925B-2369-4041-AB76-208D97AE2F35Q36085927-F7C28096-02FD-49C8-B86F-E69BAA3CC12CQ36781474-FC0E4212-B00D-4F11-90B7-AC214C2FB8CCQ37190394-F927C52E-FF82-4F7A-B6BA-D1BE0E727F3FQ37239071-506A9B37-0C4D-4EBC-A8F2-FF96DB8E762AQ38313826-6E72444E-2C84-403D-B290-5C9F0186FB56Q38330237-13CE257B-F0A5-4E39-A7FB-C510DD5679E4Q38362051-45155806-CF60-4E4F-8802-D03CE014841FQ38364234-8D2C2E98-7641-431B-843F-4C517FA9CDD1Q38616499-A60E28AD-8F1F-4E4F-BE8A-0000777EC857Q38743793-904414A8-90FF-46CE-ACDD-8A1264816539Q38776701-F47A3FD0-6821-441D-9C4E-CD84E95A6643Q38989773-746B5890-CE1E-4E60-A271-FB19A709D42BQ39208487-D164A01E-0F24-4338-961D-C0984EAFB091Q39259089-935BE111-3442-4090-A30C-5904126D33F9Q39370246-A0B4C023-6EEF-4443-ACB7-9D451FC0E479Q41391698-620B0B05-EF8D-45D7-89DC-18462F49F1FAQ41623726-BFC902B8-2169-4A0E-AF49-4BA7D5C29A85Q42396502-DD90E498-1EE3-4BD1-BEE6-DD4B097C8819Q45864012-8EFAFA49-C396-49F6-A739-EE7AC7868975Q50101341-682FE01A-73D1-45E1-8219-4CF9BAFEE22EQ54955140-9FBEDCEE-44B2-4954-954E-29A533B1B219Q55052831-B2207660-D2D8-4D53-927C-B96F52F818A2Q57193038-7B3F555F-B50A-49E3-BD38-E5D045691806Q58692202-814A653C-754E-4BE1-852C-77A5EC143560
P2860
Immunotherapy for brain cancer: recent progress and future promise
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Immunotherapy for brain cancer: recent progress and future promise
@ast
Immunotherapy for brain cancer: recent progress and future promise
@en
Immunotherapy for brain cancer: recent progress and future promise
@nl
type
label
Immunotherapy for brain cancer: recent progress and future promise
@ast
Immunotherapy for brain cancer: recent progress and future promise
@en
Immunotherapy for brain cancer: recent progress and future promise
@nl
prefLabel
Immunotherapy for brain cancer: recent progress and future promise
@ast
Immunotherapy for brain cancer: recent progress and future promise
@en
Immunotherapy for brain cancer: recent progress and future promise
@nl
P2093
P2860
P1476
Immunotherapy for brain cancer: recent progress and future promise
@en
P2093
C. G. Drake
C. M. Jackson
P2860
P304
P356
10.1158/1078-0432.CCR-13-2057
P407
P577
2014-07-15T00:00:00Z